Aziyo Biologics, Inc. (AZYO) financial statements (2022 and earlier)

Company profile

Business Address 12510 PROSPERITY DRIVE
SILVER SPRING, MD 20904
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments30,39339,150
Cash and cash equivalents30,39339,150
Restricted cash and investments35382
Receivables5,9967,166
Inventory, net of allowances, customer advances and progress billings9,55410,117
Inventory9,55410,117
Other undisclosed current assets1,4502,892
Total current assets:47,42859,707
Noncurrent Assets
Property, plant and equipment1,2001,162
Intangible assets, net (including goodwill)18,46621,865
Intangible assets, net (excluding goodwill)18,46621,865
Other noncurrent assets7676
Total noncurrent assets:19,74223,103
TOTAL ASSETS:67,17082,810
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,9578,377
Accounts payable1,5822,054
Accrued liabilities6,3756,323
Deferred revenue5533
Debt16,11812,620
Other undisclosed current liabilities1,9215,249
Total current liabilities:26,00126,779
Noncurrent Liabilities
Long-term debt and lease obligation10,41017,811
Long-term debt, excluding current maturities10,41017,811
Liabilities, other than long-term debt698756
Deferred revenue 756
Other liabilities698 
Other undisclosed noncurrent liabilities16,54016,633
Total noncurrent liabilities:27,64835,200
Total liabilities:53,64961,979
Stockholders' equity
Stockholders' equity attributable to parent, including:13,52120,831
Additional paid in capital118,599101,080
Accumulated deficit(105,091)(80,259)
Other undisclosed stockholders' equity attributable to parent1310
Total stockholders' equity:13,52120,831
TOTAL LIABILITIES AND EQUITY:67,17082,810

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Revenues47,39042,682
Cost of revenue
(Cost of Goods and Services Sold)
(28,368)(22,121)
Gross profit:19,02220,561
Operating expenses(42,054)(34,160)
Operating loss:(23,032)(13,599)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
3,579(2,567)
Interest and debt expense(5,324)(5,633)
Loss from continuing operations before income taxes:(24,777)(21,799)
Income tax expense(55)(26)
Net loss attributable to parent:(24,832)(21,825)
Preferred stock dividends and other adjustments (3,510)
Net loss available to common stockholders, diluted:(24,832)(25,335)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(24,832)(21,825)
Comprehensive loss, net of tax, attributable to parent:(24,832)(21,825)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: